Two of those molecules are Endocan (Endothelial cell-Specific Molecule 1, ESM-1) and Lumican, but only few clinical studies address their applicability in NAFLD. This evidence concerns the gene ESM1 and metabolic dysfunction-associated steatotic liver disease.